Get the Stockscreener App
16.80
2.72%
-0.47
After Hours:
17.05
0.25
+1.49%
Bicara Therapeutics Inc stock is traded at $16.80, with a volume of 275.69K.
It is down -2.72% in the last 24 hours and down -11.58% over the past month.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
See More
Previous Close:
$17.27
Open:
$17.27
24h Volume:
275.69K
Relative Volume:
0.38
Market Cap:
$920.34M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-4.55%
1M Performance:
-11.58%
6M Performance:
+90.69%
1Y Performance:
-12.13%
1-Day Range:
$16.71
$17.30
1-Week Range:
$16.71
$18.49
52-Week Range:
$7.80
$19.71
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Name
Bicara Therapeutics Inc
Sector
Industry
Phone
617-468-4219
Address
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Compare BCAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
16.80 | 946.08M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.90 | 117.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.97 | 82.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.59 | 52.94B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
844.92 | 52.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.88 | 37.84B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Mizuho | Neutral |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| May-23-25 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Apr-17-25 | Initiated | Wells Fargo | Underweight |
| Feb-06-25 | Initiated | Wedbush | Outperform |
| Dec-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
| Oct-08-24 | Initiated | Stifel | Buy |
| Oct-08-24 | Initiated | TD Cowen | Buy |
View All
Bicara Therapeutics Inc Stock (BCAX) Latest News
Hyep Ivan, Bicara Therapeutics CFO, sells $168k in BCAX stock By Investing.com - Investing.com Nigeria
Bicara Therapeutics (BCAX) Valuation After Dual Biotechnology Index Additions - Yahoo Finance
Hyep Ivan, Bicara Therapeutics CFO, sells $168k in BCAX stock - Investing.com Australia
How Bicara's Dual Biotech Index Additions Will Impact Bicara Therapeutics (BCAX) Investors - simplywall.st
The Bull Case For Bicara Therapeutics (BCAX) Could Change Following Dual Inclusion In Major Biotech Indices - Yahoo Finance
Bicara Therapeutics Inc.(NasdaqGM: BCAX) added to NASDAQ Biotechnology Index - marketscreener.com
Bicara Therapeutics Inc.(NasdaqGM:BCAX) added to S&P Biotechnology Select Industry Index - marketscreener.com
Is Bicara Therapeutics Inc. stock a defensive play in 2025July 2025 PostEarnings & Intraday High Probability Setup Alerts - Улправда
Can Bicara Therapeutics Inc. stock rebound after recent weaknessEarnings Overview Summary & Verified Swing Trading Watchlist - ulpravda.ru
Bicara Therapeutics (NASDAQ:BCAX) Raised to Hold at Mizuho - Defense World
Is Bicara Therapeutics Inc. stock trading at a premium valuationInsider Buying & AI Forecast for Swing Trade Picks - Улправда
Will Bicara Therapeutics Inc. stock deliver better than expected guidanceEarnings Recap Report & Weekly High Potential Alerts - Улправда
Published on: 2025-12-19 16:38:22 - Bölüm Sonu Canavarı
Bicara Therapeutics (NASDAQ:BCAX) Raised to "Hold" at Mizuho - MarketBeat
Will Bicara Therapeutics Inc. stock continue dividend increasesJuly 2025 Sentiment & Fast Entry High Yield Stock Tips - Улправда
What makes Bicara Therapeutics Inc. stock attractive to growth fundsFed Meeting & Technical Pattern Recognition Alerts - Улправда
Can Bicara Therapeutics Inc. stock reach $100 price target2025 Earnings Impact & Long-Term Investment Growth Plans - ulpravda.ru
Mizuho Initiates Coverage of Bicara Therapeutics (BCAX) with Neutral Recommendation - Nasdaq
Mizuho Initiates Bicara Therapeutics at Neutral With $18 Price Target - marketscreener.com
Bicara Therapeutics (BCAX) Receives Neutral Rating from Mizuho | - GuruFocus
Mizuho initiates Bicara Therapeutics stock coverage with Neutral rating By Investing.com - Investing.com Canada
Mizuho initiates Bicara Therapeutics stock coverage with Neutral rating - Investing.com
Bicara Therapeutics initiated with a Neutral at Mizuho - TipRanks
Bicara Therapeutics (NASDAQ:BCAX) COO Ryan Cohlhepp Sells 12,500 Shares - MarketBeat
Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12 - The Manila Times
Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Bicara Therapeutics Earns Relative Strength Rating Upgrade - Investor's Business Daily
Bicara announces preliminary data from phase 1b cohort of ficerafusp alfa - MSN
There is no doubt that Bicara Therapeutics Inc (BCAX) ticks all the boxes. - setenews.com
Bicara stock maintains Buy rating at Stifel after ESMO-Asia data - Investing.com Australia
Published on: 2025-12-09 02:41:05 - moha.gov.vn
Promising Efficacy and Investment Potential for Bicara Therapeutics’ FICERA in Combination with Keytruda - TipRanks
Buy Rating for Bicara Therapeutics Inc. Driven by Promising Clinical Data and Strategic Valuation - TipRanks
Bicara Therapeutics Reports Promising Phase 1b Data - TipRanks
Bicara Therapeutics Advances Dose Optimization of Potential Neck, Head Cancer Treatment - marketscreener.com
Bicara Therapeutics Inc Announces Preliminary Phase 1b Data - TradingView — Track All Markets
Promising Phase 1/1b Results and Future Prospects Boost Bicara Therapeutics’ Buy Rating - TipRanks
Bicara announces preliminary data from Phase 1b cohort of ficerafusp alfa - TipRanks
Bicara Therapeutics (Nasdaq: BCAX) Phase 1b data guide FORTIFI-HN01 dose decision for 2026 - Stock Titan
Bicara Therapeutics Inc. $BCAX Shares Acquired by Schroder Investment Management Group - MarketBeat
Bicara Therapeutics (BCAX): Reassessing Valuation After Breakthrough Therapy Designation and Strong Phase 1b Data - Yahoo Finance
Will Bicara Therapeutics Inc. stock sustain high P E ratios2025 Biggest Moves & Verified Entry Point Detection - Newser
Skandinaviska Enskilda Banken AB publ Acquires 61,201 Shares of Bicara Therapeutics Inc. $BCAX - MarketBeat
Bicara Therapeutics (BCAX) Stock Analysis Report | Financials & Insights - Benzinga
Does Bicara Therapeutics Inc (BCAX) offer a good opportunity for investors? - Setenews
Positive Outlook for Bicara Therapeutics: Promising Phase 1b Results and Safety Profile Support Buy Rating - TipRanks
Bicara Therapeutics Inc Stock (BCAX) Financials Data
There is no financial data for Bicara Therapeutics Inc (BCAX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Bicara Therapeutics Inc Stock (BCAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hyep Ivan | Chief Financial Officer |
Dec 22 '25 |
Sale |
18.31 |
9,200 |
168,492 |
145,355 |
0.08%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):